LG Chem renews license triggering $2M payment to Avacta
South Korean clinical stage biopharmaceutical company, LG Chem Life Sciences, has triggered a license renewal…
June 30, 2022 - 2 minutes
Checkpoint Inhibitors
Keep yourself up to date with the latest checkpoint inhibitor news. This section includes updates on clinical trials, approvals, collaboration deals, and technology advancements on checkpoint inhibitor therapy.
Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy
Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled…
May 13, 2022 - 4 minutes
GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos
Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month,…
June 30, 2021 - 5 minutes
BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
April 29, 2021 - 5 minutes
Artificial Intelligence Could Beat Tumors Resistant to Immunotherapy
The French company OSE Immunotherapeutics has signed a partnership to use artificial intelligence to develop…
March 27, 2019 - 2 minutes
Innate’s Cancer Immunotherapy Combo Beats Standard Treatment Twofold
A combination cancer immunotherapy from French biotech Innate Pharma was twice as effective at treating…
October 22, 2018 - 2 minutes
Replimune’s €85M IPO set to Boost Oncolytic Immunotherapy Pipeline
The US-UK biotech completed its $100M (€85M) IPO on the NASDAQ stock exchange to further…
July 26, 2018 - 2 minutes
Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug”
Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer…
July 24, 2018 - 6 minutes
Massive Series B Funding Could Bring Belgian Immuno-oncology Treatments Into the Clinic
iTeos Therapeutics raised €65M ($75M) to bring two of its cancer treatments into the clinic…
June 20, 2018 - 2 minutes
Genmab and Janssen Suffer Combination Therapy Setback
Janssen will discontinue a Phase I study testing Danish biotech Genmab's blood cancer blockbuster daratumumab…
May 28, 2018 - 2 minutes
Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?
Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much…
April 9, 2018 - 4 minutes
Boehringer Offers €1Bn for New Checkpoint Inhibitor from a French Biotech
OSE Immunotherapeutics could receive up to €1.1Bn from its new partner Boehringer Ingelheim, which has…
April 5, 2018 - 2 minutes
